周围神经病变涵盖多种病情——糖尿病性、特发性、化疗相关性、缺血性——以进行性神经纤维丧失、脱髓鞘和感觉运动功能障碍为特征。干细胞疗法开发多个途径：胎盘间充质干细胞（MSCs）分泌神经营养因子（NGF、GDNF、VEGF），促进神经再生和血管新生；神经源性细胞分化为功能性神经元以替代损伤的神经纤维；外泌体将生长因子货物直接运送至受影响的外周组织。治疗原理结合神经保护（阻止进一步退化）、神经再生性修复（存活轴突发芽）和血管恢复（改善缺血性神经病变）。46项注册试验调查疗效跨越神经病变亚型；8项主动招募患者，表明临床容量和商业兴趣不断扩展。
肌内或全身胎盘MSC注射的已发表试验报告，糖尿病性神经病变患者中45-60%感觉功能改善，疼痛神经病变患者群体中50-70%疼痛减轻。电生理学终点（神经传导速度、F波潜伏期）在应答者中显示适度改善。一项第二阶段糖尿病性神经病变试验（80名患者）发现，治疗组与假注射组相比，12个月时神经病理性疼痛评分降低40-50%。神经源性细胞疗法研究较少；早期试验显示安全信号但疗效数据有限。外泌体疗法正在出现，小型概念验证提示化疗相关性神经病变疼痛减少和感觉改善。
神经病变细胞疗法成本为€4,000-6,500，取决于给药方法和细胞来源。全身静脉MSC输液（€4,500-5,500）最易获取。肌内或靶向鞘内注射（€5,500-7,000）提供更高的局部浓度，但需要专业置入。外泌体疗法（€4,000-5,500）定价具有竞争力。3-6个月期间多次输液常被推荐，总成本增加到€8,000-13,000。保险很少报销；自付费用在全球范围内是标准做法，尽管一些地区性试验为入选患者提供免费或补贴的获取途径。
Cell therapy for Peripheral Neuropathy is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently 研究性. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Peripheral Neuropathy programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估